Description
Erlocip 150mg (Erlotinib) Tablets
Erlocip 150mg contains erlotinib, a prescription kinase inhibitor used to treat certain types of cancer. In particular, erlotinib is used for specific patients with non-small cell lung cancer (NSCLC) and, in combination with gemcitabine, for certain patients with advanced pancreatic cancer.
Importantly, erlotinib treatment depends on the cancer type, molecular characteristics, previous treatment, and overall clinical condition. Therefore, a qualified healthcare professional should determine whether Erlocip 150mg is appropriate.
Erlocip 150mg Erlotinib: Quick Answer
Erlocip 150mg is a prescription medicine containing erlotinib. Erlotinib belongs to the tyrosine kinase inhibitor class and works by blocking EGFR signaling involved in the growth of certain cancer cells.
For U.S. labeling, 150mg once daily is the recommended erlotinib dose for the indicated NSCLC use, while 100mg is the labeled dose used with gemcitabine for pancreatic cancer. Erlotinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food.
What is Erlocip 150mg?
Erlocip 150mg is an oral prescription tablet containing erlotinib. The product shown on this page is manufactured by Cipla and contains erlotinib hydrochloride as the active pharmaceutical ingredient.
Erlotinib is a targeted anticancer medicine. Unlike traditional cytotoxic chemotherapy, it specifically interferes with signaling pathways that can promote the growth and multiplication of certain cancer cells.
Erlocip 150mg Uses
Erlocip 150mg may be prescribed for certain cancer patients when erlotinib is considered clinically appropriate.
- Specific types of non-small cell lung cancer (NSCLC).
- Locally advanced or metastatic NSCLC with specified EGFR mutations under applicable labeling.
- Advanced pancreatic cancer when erlotinib is prescribed in combination with gemcitabine.
However, erlotinib is not suitable for every patient with lung or pancreatic cancer. Tumor testing, cancer stage, previous treatment, and other clinical factors can influence treatment selection.
Erlotinib for Lung Cancer
Erlotinib is a targeted therapy used for certain forms of NSCLC. Current U.S. labeling recommends selecting patients with metastatic NSCLC based on the presence of specific EGFR alterations, including EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Because targeted medicines work according to specific tumor characteristics, molecular testing can help healthcare professionals determine whether erlotinib may be an appropriate treatment option.
How Does Erlotinib Work?
Erlotinib is a tyrosine kinase inhibitor. It blocks the activity of the epidermal growth factor receptor (EGFR), a protein involved in signaling that can encourage cancer-cell growth.
When cancer cells depend on abnormal EGFR signaling, blocking this pathway can slow or inhibit cancer-cell growth. Nevertheless, the response varies between patients and depends on the biology of the cancer.
Erlocip 150mg Composition
The active ingredient in Erlocip 150mg is erlotinib, supplied as erlotinib hydrochloride.
The exact inactive ingredients may vary according to the manufacturer and formulation. Check the product packaging or package insert for the complete ingredient information.
How to Take Erlocip 150mg
Take Erlocip 150mg exactly as prescribed by your oncologist. Do not change the dose or treatment schedule without professional medical advice.
U.S. prescribing information recommends taking erlotinib on an empty stomach, at least 1 hour before or 2 hours after eating. For the indicated NSCLC use, the labeled dose is 150mg once daily.
Swallow the tablet as directed with water. Your healthcare professional may reduce, interrupt, or discontinue treatment if significant adverse reactions occur.
If you miss a dose, follow the instructions provided by your healthcare professional or prescription label. Do not take extra tablets to compensate for a missed dose unless your healthcare professional specifically tells you to do so.
Erlocip 150mg Price
The price of Erlocip 150mg can vary according to location, supplier, package size, availability, prescription requirements, and shipping costs.
For current availability and pricing, visit our online medicine shop or browse our medicine categories.
For U.S. customers, prescription-drug dispensing, importation, and use are subject to applicable federal and state requirements.
Erlocip 150mg Side Effects
Erlotinib can cause side effects. Some reactions are common and manageable, while others require prompt medical evaluation.
Common Erlotinib Side Effects
- Skin rash
- Diarrhea
- Loss of appetite
- Fatigue
- Nausea
- Vomiting
- Dry skin
- Itching
- Stomatitis or mouth irritation
- Abdominal discomfort
Skin rash and diarrhea are among the commonly reported adverse reactions with erlotinib.
Serious Erlotinib Side Effects
Some adverse reactions can be serious. Contact a healthcare professional promptly if you develop new or worsening breathing problems, severe diarrhea, significant skin reactions, severe abdominal pain, vision problems, unusual bleeding, or symptoms of liver problems.
U.S. labeling includes warnings concerning interstitial lung disease, renal failure, hepatotoxicity, gastrointestinal perforation, serious skin disorders, ocular disorders, bleeding with certain anticoagulants, and embryo-fetal toxicity.
Erlocip 150mg Precautions
Before taking erlotinib, tell your healthcare professional about your medical history and all medicines you currently use.
- Tell your doctor about liver or kidney problems.
- Report previous or current lung problems.
- Tell your healthcare professional about stomach or intestinal disorders.
- Inform your doctor about eye problems.
- Tell your doctor if you are pregnant, planning a pregnancy, or breastfeeding.
- Discuss all prescription medicines, over-the-counter medicines, vitamins, and supplements.
- Avoid unnecessary or prolonged sunlight exposure because erlotinib can cause or worsen skin reactions.
Smoking can also reduce erlotinib exposure and may affect treatment effectiveness. Therefore, discuss tobacco use with your healthcare professional.
Erlotinib Drug Interactions
Erlotinib can interact with other medicines and substances. In particular, medicines that alter stomach acidity or affect CYP3A4 and related metabolic pathways can change erlotinib exposure.
Antacids may need to be separated from erlotinib by several hours. Proton-pump inhibitors, H2 blockers, certain antibiotics, antifungals, seizure medicines, anticoagulants, and herbal products such as St. John’s wort can also require special consideration.
Always provide your healthcare professional with a complete list of medicines and supplements before starting erlotinib.
Erlocip 150mg Warnings
Erlotinib should be used under appropriate medical supervision. Seek urgent medical attention for sudden or worsening shortness of breath, cough, fever, severe diarrhea, severe skin reactions, eye symptoms, or significant abdominal pain.
Healthcare professionals may monitor liver function and other clinical parameters during treatment. Treatment interruption, dose reduction, or discontinuation may be necessary when serious toxicity develops.
Erlocip 150mg and Tarceva
Tarceva is a U.S. brand associated with erlotinib. Erlocip is a separate branded product containing erlotinib hydrochloride.
Therefore, patients should not assume that different erlotinib brands have identical regulatory status, packaging, availability, or approval in every country.
FDA Information About Erlotinib
Erlotinib received its initial U.S. approval in 2004. U.S. labeling identifies 25mg, 100mg, and 150mg tablet strengths. The labeled NSCLC dose is 150mg once daily on an empty stomach, while the pancreatic cancer regimen uses 100mg once daily with gemcitabine.
For metastatic NSCLC, current U.S. labeling specifies selection based on certain EGFR mutations. FDA-approved companion diagnostic information also identifies EGFR exon 19 deletions and exon 21 L858R alterations in relation to erlotinib treatment.
Important: FDA approval of erlotinib as an active medicine does not automatically mean that the specific international brand shown on this page is FDA-approved for U.S. marketing. Patients should verify the exact product and regulatory status before use in the United States.
U.S. Medical Information Sources
MedlinePlus: Erlotinib Drug Information
FDA: Authorized Companion Diagnostic Devices
Erlotinib Alternatives and Substitutes
Alternative cancer treatments depend on the tumor type, EGFR status, disease stage, previous treatment, overall health, and treatment goals.
Other targeted therapies may be considered when clinically appropriate. However, medicines such as osimertinib, afatinib, or gefitinib are not automatically interchangeable with erlotinib. An oncologist should determine the most appropriate treatment based on the patient’s cancer characteristics.
Frequently Asked Questions About Erlocip 150mg
What is Erlocip 150mg used for?
Erlocip 150mg contains erlotinib and is used for certain types of non-small cell lung cancer. Erlotinib also has a pancreatic cancer indication when used with gemcitabine, although the labeled pancreatic dose is 100mg rather than 150mg.
What is the active ingredient in Erlocip 150mg?
The active ingredient is erlotinib, supplied as erlotinib hydrochloride.
Is Erlocip 150mg a chemotherapy medicine?
Erlotinib is a targeted anticancer medicine and tyrosine kinase inhibitor. It works by interfering with EGFR signaling rather than acting like traditional cytotoxic chemotherapy.
How should Erlocip 150mg be taken?
Follow your oncologist’s instructions. U.S. labeling recommends the 150mg NSCLC dose once daily on an empty stomach, at least 1 hour before or 2 hours after food.
Can Erlocip 150mg cause a skin rash?
Yes. Skin rash is one of the common adverse reactions associated with erlotinib. Contact your healthcare professional if the rash becomes severe or causes significant discomfort.
Can Erlocip 150mg cause diarrhea?
Yes. Diarrhea is a common side effect of erlotinib. Severe or persistent diarrhea can lead to dehydration and requires prompt medical attention.
Is Erlocip 150mg FDA approved?
Erlotinib is an FDA-approved active medicine with specific U.S. indications. However, approval of the active ingredient does not automatically establish FDA approval of the specific Erlocip brand shown on this page.
Buy Erlocip 150mg Online
If you are looking for Erlocip 150mg, carefully verify the product name, strength, manufacturer, packaging, prescription requirements, and applicable regulations before ordering.
Shop Prescription Medicines |
Browse Medicine Categories
U.S. Regulatory Notice: Erlocip 150mg is an internationally branded prescription medicine. Availability, dispensing, importation, and use of prescription medicines in the United States are subject to applicable federal and state laws. Do not assume that an international brand is FDA-approved simply because its active ingredient has an FDA-approved product. Verify the exact product and regulatory status with a licensed healthcare professional and appropriate U.S. regulatory resources.
Medical Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Erlocip 150mg (erlotinib) should be used only according to a qualified healthcare professional’s prescription and instructions.
Do not start, stop, or change cancer treatment based solely on information on this website. Always discuss potential benefits, risks, drug interactions, pregnancy considerations, and monitoring requirements with your oncologist or pharmacist.
Reviews
There are no reviews yet.